Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP202 for prevention of postoperative atrial fibrillation after CABG or valve surgery
ACTRN12619000658112Phase 3Not yet recruiting
- Sponsor
- Armaron Bio
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of NP202 in Atrial fibrillation (AFib) (2 arms), sponsored by Armaron Bio. Primary endpoint: Incidence of postoperative atrial fibrillation. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
NP202
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ACTRN12619000658112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000658112.